Sign up to our newsletter below.

First name
Last name
Email
Company
Job Title
Industry
We see you're using an obsolete browser. For a better experience when browsing The New Economy, and for a better web, please consider switching to a newer browser. For more information on popular browsers please see browsehappy.com.
Digital editions
Link to digital editions
Link to Digital Symphony
Link to Regenerative Healthcare
Link to Waste Management
Link to SAP
Link to IBM
Link to Ingenuity Lab
Link to Carnival Corporation
Link to The New Economy Awards 2016

  • Sustainable Innovation Forum 2016
  • Cloud Computing Forum 2015
  • World Pension Sumit 2015
  • Broadband World Forum 2015
  • Mobile World Congress

Insights

Nuclear waste will remain a deadly threat for hundreds of thousands of years. Despite having decades of hazardous waste in temporary storage, the world is only now finalising plans for long-term containment

Onkalo aims to solve the 100,000-year problem of nuclear waste storage

Nuclear waste will remain a deadly threat for hundreds of thousands of years. Despite having decades of hazardous waste in temporary storage, the world is only now finalising plans for long-term containment

Social network participation among Fortune 500 CEOs Positive trends point to a US embrace of solar power

Pharmaceuticals

Business The discovery of stress granules and their role in neurodegenerative disease has opened up new possibilities for the treatment of ALS and Alzheimer’s disease, according to Aquinnah Pharmaceuticals

Aquinnah offers new hope for ageing brains

The discovery of stress granules and their role in neurodegenerative disease has opened up new possibilities for the treatment of ALS and Alzheimer’s disease, according to Aquinnah Pharmaceuticals

Business Japan's biggest pharmaceutical company sets its sights on foreign takeovers as it looks to bolster its position in the global drugs market

Japan’s Takeda sets aside $15bn for US pharmaceutical acquisitions

Japan’s biggest pharmaceutical company sets its sights on foreign takeovers as it looks to bolster its position in the global drugs market

Technology Drug developer ImmuPharma successfully raises £8.4m to fund final trial of breakthrough lupus treatment

Gold-standard lupus treatment Lupuzor begins phase III trial

Drug developer ImmuPharma successfully raises £8.4m to fund final trial of breakthrough lupus treatment

Technology Regulation has always struggled to keep pace with technology. Here are five of the biggest clashes between lawmen and innovators

Five times technology clashed with the law

Regulation has always struggled to keep pace with technology. Here are five of the biggest clashes between lawmen and innovators

Business Imperial, Cambridge and UCL partner up with industry leaders AstraZeneca, GlaxoSmithKline and Johnson & Johnson to advance new treatments

Pharmaceutical giants launch consortium with top universities

Imperial, Cambridge and UCL partner up with industry leaders AstraZeneca, GlaxoSmithKline and Johnson & Johnson to advance new treatments

Business Pfizer, the US’s biggest pharmaceutical company, has its sights set on another huge takeover

Biggest pharma merger in talks

Pfizer, the US’s biggest pharmaceutical company, has its sights set on another huge takeover

Concerning: ,
Technology Seen as a major breakthrough in cancer treatment, immuno-oncology could be the hope the world has waited for

Immuno-oncology provides hope to cancer patients

Seen as a major breakthrough in cancer treatment, immuno-oncology could be the hope the world has waited for

Technology The New Economy speaks to Dr John Ashton, President of the UK Faculty of Public Health, to ask whether the pharmaceutical industry needs to invest more in curing diseases seen to be less profitable

Is the pharma industry washing its hands of Ebola? | Video

The New Economy speaks to Dr John Ashton, President of the UK Faculty of Public Health, to ask whether the pharmaceutical industry needs to invest more in curing diseases seen to be less profitable

Concerning:
Business US pharma giant ups stakes in bid for UK firm; AstraZeneca board rejects offer, while politicians raise concerns over potential job losses

Pfizer’s increased bid rejected by AstraZeneca board

US pharma giant ups stakes in bid for UK firm; AstraZeneca board rejects offer, while politicians raise concerns over potential job losses

Featured Part 2 of 2: Having overcome patent expirations, and accusations of corruption in China, what does the future hold for pharmaceutical giant GlaxoSmithKline Pharmaceutical? Rita Lobo explores...

A titan will quake

Part 2 of 2: Having overcome patent expirations, and accusations of corruption in China, what does the future hold for pharmaceutical giant GlaxoSmithKline Pharmaceutical? Rita Lobo explores…

Technology The New Economy interviews Dimitri Dimitriou, CEO of Immupharma, on how its drug Lupuzor has been cleared for fast track approval

Dimitri Dimitriou on Lupuzor | Immupharma | Video

The New Economy interviews Dimitri Dimitriou, CEO of Immupharma, on how its drug Lupuzor has been cleared for fast track approval

Concerning:
Technology The New Economy interviews Gordon McCauley, CEO and President of Allon Therapeutics, on a treatment for neuro-degenerative diseases

Gordon McCauley on healthcare | Allon Therapeutics | Video

The New Economy interviews Gordon McCauley, CEO and President of Allon Therapeutics, on a treatment for neuro-degenerative diseases

Concerning: